Brown TM, Vera-Llonch M, Kanu C, Sikora Kessler A, Yarlas A, Fehnel SE. Cross-sectional quantitative evaluation of a novel patient-reported outcome measure in familial chylomicronemia syndrome. Patient Relat Outcome Meas. 2024 Feb 15;15:45-59. doi: 10.2147/PROM.S441583
Khan AH, Kosa K, De Prado Gomez L, Whalley D, Kamat S, Clark M. Content validation of patient-reported sleep measures and development of a conceptual model of sleep disturbance in patients with moderate-to-severe, uncontrolled asthma. Patient Relat Outcome Meas. 2023 Mar 23;14:57-71. doi: 10.2147/PROM.S392666
Coles T, Chen K, Nelson L, Harris N, Vera-Llonch M, Krasner A, Martin S. Psychometric evaluation of the hypoparathyroidism symptom diary. Patient Relat Outcome Meas. 2019 Jan 29;2019(10):25-36. doi: 10.2147/PROM.S179310
Yosipovitch G, Reaney M, Eckert L, Nelson L, Clark M, Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis. Poster presented at the Australasian College of Dermatologists 50th Annual Scientific Meeting; May 2017. Sydney, Australia. [abstract] Australas J Dermatol. 2017 May; 58(S1):106-7. Previously presented at the 2017 American Academy of Dermatology Annual Meeting. doi: 10.1111/ajd.21_12652
Spelman LJ, Lebwohl M, Mordin M, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):73.
Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.
Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.
Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients. J Drugs Dermatol. 2015 Feb;14(2):159-66.
Eastman WJ, Malahias S, Delconte J, DiBenedetti D. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014 Jul;94(1):46-53.
Akashi-Ronquest N. The impact of biological preferences on parental investments in children and step-children. Rev Econ Househ. 2009 Mar 1;7(1):59-81.
Van Houtven CH, Wilson MR, Clipp EC. Informal care intensity and caregiver drug utilization. Rev Econ Househ. 2005;3(4):415-33.